AbbVie has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV). The NDA is for the treatment of adults with chronic genotype 4 (GT4) hepatitis C virus (HCV) infection. continue reading: bit.ly/1Hhn3Ow
FDA Grants Priority Review for AbbVie... - HFI Connect - Hep...
FDA Grants Priority Review for AbbVie's Hepatitis C Treatment
Written by
mwright
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
Just found out I have Hep B and have red spots all over is that normal.
Hello everyone, I recently went to the doctors for food poisoning and found out I have typhiod and...
Hepatitis E
I got infected by Hepatitis E two months ago and i am still suffering from this. My highest...
Overwhelmed
Hi everyone, I'm new to this site and really just looking for somewhere I can talk to people that...
